Eisai, Biogen battered by controversy over PhII Alzheimer's study after posting positive results
At first blush, Eisai and Biogen posted the kind of promising data for BAN2401 that might have overcome some doubts about its potential as a treatment for Alzheimer’s, a field marked by the wreckage of repeated, high profile failures. But instead of cheering on evidence of success, a large group of analysts last night zeroed in on a crucial change in the study that could have confounded the data presented — and now we have a brand new controversy to add to the literature of Alzheimer’s.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
